<DOC>
	<DOCNO>NCT00439140</DOCNO>
	<brief_summary>This study ass safety efficacy botulinum toxin Type A treatment urinary incontinence overactive bladder patient spinal cord injury multiple sclerosis .</brief_summary>
	<brief_title>Safety Efficacy Study Botulinum Toxin Type A Treatment Neurogenic Overactive Bladder</brief_title>
	<detailed_description>Botulinum toxin Type A 300U discontinue study regulatory approval botulinum toxin Type A 200U . Patients remain study allocate receive botulinum toxin Type A 300U treatment 2 ( yet receive ) receive botulinum toxin Type A 200U instead .</detailed_description>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Urinary incontinence result neurogenic overactive bladder due spinal cord injury multiple sclerosis Inadequate response anticholinergic medication use treat overactive bladder . Neurological respiratory impairment abnormal pulmonary function test result History evidence pelvic urologic abnormality Previous current diagnosis bladder prostate cancer Symptomatic untreated urinary tract infection time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>